...
首页> 外文期刊>Gynecologic Oncology: An International Journal >MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
【24h】

MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.

机译:肿瘤来源的外泌体的MicroRNA标记作为卵巢癌的诊断生物标记物。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Most ovarian cancer patients are diagnosed at an advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. While expression patterns of a recently identified biomarker family, microRNA, appear to be characteristic of tumor type and developmental origin, microRNA profiling has been limited to tissue specimens. Tumors actively release exosomes into the peripheral circulation and we now demonstrate the association of microRNAs with circulating tumor-derived exosomes. METHODS: Circulating tumor exosomes were isolated using a modified MACS procedure with anti-EpCAM. Initially, microRNA profiles of ovarian tumors were compared to those of tumor exosomes isolated from the same patients. Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer. RESULTS: MicroRNA from ovarian tumor cells and exosomes from the same patients were positive for 218 of 467 mature microRNAs analyzed. The levels of the 8 specific microRNAs were similar between cellular and exosomal microRNAs (exhibiting correlations from 0.71 to 0.90). While EpCAM-positive exosomes were detectable in both patients with benign ovarian disease and ovarian cancer, exosomal microRNA from ovarian cancer patients exhibited similar profiles, which were significantly distinct from profiles observed in benign disease. Exosomal microRNA could not be detected in normal controls. CONCLUSIONS: These results suggest that microRNA profiling of circulating tumor exosomes could potentially be used as surrogate diagnostic markers for biopsy profiling, extending its utility to screening asymptomatic populations.
机译:目的:大多数卵巢癌患者被诊断为晚期(67%),生存率显着提高的前景在于早期诊断。虽然最近鉴定出的生物标志物家族microRNA的表达模式似乎是肿瘤类型和发育起源的特征,但microRNA分析仅限于组织标本。肿瘤主动将外泌体释放到周围循环中,我们现在证明了microRNA与循环肿瘤衍生外泌体的关联。方法:采用改良的MACS程序与抗EpCAM分离循环肿瘤外泌体。最初,将卵巢肿瘤的microRNA图谱与从同一患者中分离的肿瘤外泌体的图谱进行了比较。在从血清标本中分离出的外泌体中比较了先前被证实可诊断的8种microRNA(miR-21,miR-141,miR-200a,miR-200c,miR-200b,miR-203,miR-205和miR-214)的水平良性疾病和卵巢癌各个阶段的女性结果:来自卵巢癌细胞的微小RNA和来自同一患者的外泌体在分析的467个成熟微小RNA中有218个呈阳性。细胞和外体microRNA之间的8种特异性microRNA的水平相似(相关性从0.71到0.90)。虽然在患有卵巢良性疾病和卵巢癌的患者中均可检测到EpCAM阳性外泌体,但来自卵巢癌患者的外泌体microRNA表现出相似的特征,这与在良性疾病中观察到的特征明显不同。在正常对照中无法检测到外泌体microRNA。结论:这些结果表明,循环肿瘤外泌体的microRNA分析可能被用作活检分析的替代诊断标记,将其实用性扩展到筛查无症状人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号